

**Reference Number:** FOI202223/111  
**From:** Commercial  
**Date:** 10 June 2022  
**Subject:** Number of patients treated for any disease with a list of drugs and source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality) for migraine

Q1 How many patients have been treated with the following drugs in the past 4 months:  
a. Erenumab (Aimovig) – for any disease  
b. Fremanezumab (Ajoovy) – for any disease  
c. Galcanezumab (Emgality) – for any disease  
d. Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – for migraine ONLY

A1  
a. Zero  
b. Zero  
c. Zero  
d. Zero

Q2 I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality) for migraine. Could you please answer the following questions:  
a. Does the trust commission/fund Botulinum Toxin treatment for migraine (Y/N)?  
b. Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?  
c. In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.  
d. In case the trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

A2  
a. No  
b. No  
c. Funded by Local CCG Commissioners  
d. Not applicable as per above